Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the...

Related Keywords

United States ,American ,Setha Gross ,Thomasf Imperiale ,Megan Jones ,Paul Limburg ,Lindsey Dickinson ,Prnewswire Exact Sciences Corp ,Us Preventive Services Task ,Grossman School Of Medicine ,Genomic Health Inc ,Facebook ,American Joint Committee On Cancer Staging System ,Sciences Corp ,Exchange Commission ,Linkedin ,American College Of Gastroenterology ,Twitter ,National Comprehensive Cancer Network ,American Cancer Society ,Sciences Corporation ,Nasdaq ,Regenstrief Institute ,United States Census Bureau ,Indiana University School Of Medicine ,American College ,Annual Meeting ,American Joint Committee ,Cancer Staging System ,Indiana University School ,Analysis Presented ,Supports Performance ,Next Generation Cologuard ,Exact Sciences ,Mayo Clinic ,Exact Science ,New England Journal ,Services Task Force ,Genomic Health ,Risk Factors ,Annual Report ,Quarterly Reports ,States Census ,Annual Estimates ,Resident Population ,Single Year ,Exact Sciences Corp ,